The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10087 malaria professionals are enjoying the free benefits of MalariaWorld today

Scientific Articles

Clinical expression and antigenic profiles of a Plasmodium vivax vaccine candidate: merozoite surface protein 7 (PvMSP-7)

June 14, 2019 - 18:16 -- Open Access
Chew Weng Cheng, Somchai Jongwutiwes, Chaturong Putaporntip and Andrew P. Jackson
Malaria Journal 2019 18:197, 13 June 2019

Vivax malaria is the predominant form of malaria outside Africa, affecting about 14 million people worldwide, with about 2.5 billion people exposed. Development of a Plasmodium vivax vaccine is a priority, and merozoite surface protein 7 (MSP-7) has been proposed as a plausible candidate. The P. vivax genome contains 12 MSP-7 genes, which contribute to erythrocyte invasion during blood-stage infection. Previous analysis of MSP-7 sequence diversity suggested that not all paralogs are functionally equivalent. To explore MSP-7 functional diversity, and to identify the best vaccine candidate within the family, MSP-7 expression and antigenicity during bloodstream infections were examined directly from clinical isolates.

Not Open Access | Unconventional secretory pathway activation restores hair cell mechanotransduction in an USH3A model

June 14, 2019 - 18:14 -- NOT Open Access
Suhasini R. Gopal, Yvonne T. Lee, Ruben Stepanyan, Brian M. McDermott Jr., and Kumar N. Alagramam
PNAS May 28, 2019 116 (22) 11000-11009

The pathogenic variant c.144T>G (p.N48K) in the clarin1 gene (CLRN1) results in progressive loss of vision and hearing in Usher syndrome IIIA (USH3A) patients.

Not Open Access | Can therapeutically-rational exchange (T-REX) of type-O red blood cells (RBCs) benefit Plasmodium falciparum malaria patients?

June 14, 2019 - 18:07 -- NOT Open Access
Ryan P.Jajosky, Ryan P.Jajosky, Philip G.Jajosky, Audrey N.Jajosky, Philip G.Jajosky
Transfusion and Apheresis Science Volume 58, Issue 3, June 2019, Pages 344-345

New therapies are needed to reduce the morbidity and mortality caused by Plasmodium falciparum malaria.

CXCR4 regulates Plasmodium development in mouse and human hepatocytes

June 14, 2019 - 18:04 -- Open Access
Hironori Bando, Ariel Pradipta, Masahiro Yamamoto, et al.
Journal of Experimental Medicine June 3, 2019 Volume 216, No. 6

The liver stage of the etiological agent of malaria, Plasmodium, is obligatory for successful infection of its various mammalian hosts.

Plasmodium knowlesi as a model system for characterising Plasmodium vivax drug resistance candidate genes

June 11, 2019 - 15:08 -- Open Access
Lisa H. Verzier, Rachael Coyle, Shivani Singh, Theo Sanderson, Julian C. Rayner
PLoS Negl Trop Dis 13(6): e0007470

Plasmodium vivax causes the majority of malaria outside Africa, but is poorly understood at a cellular level partly due to technical difficulties in maintaining it in in vitro culture conditions.

Linking human behaviours and malaria vector biting risk in south-eastern Tanzania

June 11, 2019 - 15:07 -- Open Access
Marceline F. Finda, Irene R. Moshi, Fredros O. Okumu, et al.
PLoS ONE 14(6): e0217414

To accelerate malaria elimination in areas where core interventions such as insecticide-treated nets (ITNs) are already widely used, it is crucial to consider additional factors associated with persistent transmission.


An ortholog of Plasmodium falciparum chloroquine resistance transporter (PfCRT) plays a key role in maintaining the integrity of the endolysosomal system in Toxoplasma gondii to facilitate host invasion

June 11, 2019 - 15:05 -- Open Access
L. Brock Thornton, Paige Teehan, Zhicheng Dou, et al.
PLoS Pathog 15(6): e1007775

Toxoplasma gondii is an apicomplexan parasite with the ability to use foodborne, zoonotic, and congenital routes of transmission that causes severe disease in immunocompromised patients.

Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents

June 11, 2019 - 15:02 -- Open Access
Barbara H. Stokes, Euna Yoo, David A. Fidock, et al.
PLoS Pathog 15(6): e1007722

Therapeutics with novel modes of action and a low risk of generating resistance are urgently needed to combat drug-resistant Plasmodium falciparum malaria.

Medical Treatment: 

The contribution of non-malarial febrile illness co-infections to Plasmodium falciparum case counts in health facilities in sub-Saharan Africa

June 11, 2019 - 14:52 -- Open Access
Ursula Dalrymple, Ewan Cameron, Peter W. Gething, et al.
Malaria Journal 2019 18:195, 11 June 2019

The disease burden of Plasmodium falciparum malaria illness is generally estimated using one of two distinct approaches: either by transforming P. falciparum infection prevalence estimates into incidence estimates using conversion formulae; or through adjustment of counts of recorded P. falciparum-positive fever cases from clinics. Whilst both ostensibly seek to evaluate P. falciparum disease burden, there is an implicit and problematic difference in the metric being estimated. The first enumerates only symptomatic malaria cases, while the second enumerates all febrile episodes coincident with a P. falciparum infection, regardless of the fever’s underlying cause.

Plasmodium falciparum merozoite surface antigen-specific cytophilic IgG and control of malaria infection in a Beninese birth cohort

June 11, 2019 - 14:50 -- Open Access
Rafiou Adamou, Célia Dechavanne, David Courtin, et al.
Malaria Journal 2019 18:194, 11 June 2019

Substantial evidence indicates that cytophilic IgG responses to Plasmodium falciparum merozoite antigens play a role in protection from malaria. The specific targets mediating immunity remain unclear. Evaluating antibody responses in infants naturally-exposed to malaria will allow to better understand the establishment of anti-malarial immunity and to contribute to a vaccine development by identifying the most appropriate merozoite candidate antigens.


Subscribe to Scientific Articles